Apple shares closed lower in the US Wednesday, ahead of the tech innovator’s event at which it unveiled three new versions of its iPhone X and a new Smart Watch with FDA approval. The smartphones aren’t hugely different from the original X; however, one is a lower priced option.
Apple shares ended the US Wednesday session 1.24% lower at $221.07. However, the stock is a little higher in out-of-hours activity.
New iPhone X launch
At an event on its campus in Cupertino Wednesday, Apple shared the details of its latest iPhone offerings.
The iPhone Xs, Xs Max and Xr are all variations on the iPhone X. The Xs is the same size, the Xs Max is larger and the Xr is larger than the original, but has a lower quality LCD screen than the OLED screens on the other options.
The UK price points for these phones are:
- Xs will cost the same as the X, from £999.
- Xs Max will be more expensive, starting from £1,099.
- Xr will be a little more affordable, coming in at a starting price of £749.
“iPhone Xs is packed with next-generation technologies and is a huge step forward for the future of the smartphone,” said Apple’s senior VP of Worldwide marketing, Philip Schiller. “Everything is state of the art.”
Apple also launched an updated version of it smart watch. The Apple Watch 4 series has a similar sized face as the previous version, however, the end-to-end design means the screen display is notably larger.
One major upgrade to the tech firm’s new watch, is its sensors are able to detect if the wearer has an irregular heart rhythm. In addition, the watch can also measure of the user’s heart rate is beating unusually slow or fast, on a day-to-day basis.
The abilities of the app have been given FDA approval in the US. While that shows the watch can reliably operate in that way, it’s also been made clear by regulators – and Apple – that the watch shouldn’t be considered as a replacement for traditional medical diagnostic equipment.